Introduction to the main pharmacological mechanisms and targets of lorlatinib

Lorlatinib is a third-generation anaplastic lymphoma kinase (ALK) and c-ROSproto-oncogene1 (ROS1) tyrosine kinase inhibitor, mainly used to treat ALK or ROS1 gene rearrangement-positive non-small cell lung cancer (NSCLC). As a new generation of targeted drugs, lorlatinib is specially designed to overcome the resistance caused by previous generations of ALK inhibitors (such as crizotinib, ceritinib and alectinib). It is especially effective in treating brain metastases and can penetrate the blood-brain barrier to provide more durable disease control for patients with advanced NSCLC.

From a pharmacological mechanism, lorlatinib selectively inhibits the tyrosine kinase activities of ALK and ROS1 and blocks the downstream signaling pathways mediated by them, thereby inhibiting the proliferation and survival of cancer cells. It is particularly potent against ALK gene mutation sites (such as the G1202R mutation), which often cause patients to become resistant to previous generations of ALK inhibitors. Compared with other ALK inhibitors, lorlatinib exhibits higher affinity and selectivity in inhibiting mutant activity.

In terms of target effects, lorlatinib not only highly selectively targets ALK and ROS1, but also targets a variety of ALKSecondary mutations are active, including L1196M, G1269A, etc. This allows it to show significant efficacy in treating patients who have experienced failure of other ALK inhibitors. At the same time, lorlatinib can also effectively enter the central nervous system and show significant anti-tumor activity against brain metastases. It is currently one of the few ALK inhibitors that can comprehensively cover systemic and central lesions.

In short, the pharmacological mechanism and target specificity of lorlatinib make it play an important role in the treatment of NSCLC. Its high efficiency inhibitsALK/ROS1The activity, wide coverage of mutation spectrum and excellent central penetration not only bring new treatment hope to patients with refractory lung cancer, but also promote the development of precision medicine in the field of lung cancer. As more clinical research data accumulates, the application prospects of lorlatinib will become clearer and broader.

Reference materials:https://www.drugs.com/